Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

reloxin weekly for three weeks, was reported. Eleven patients achieved a complete remission (CR) or complete remission without full platelet recovery (CRp), for an overall remission rate of 38 percent. The 30-day all-cause mortality rate was 17 percent, which compares favorably to standard induction chemotherapy. Data on the median duration of response for patients achieving a CR or CRp in Schedule A is not yet available.

With Schedule B, 72 mg/m2 of voreloxin weekly for two weeks, Sunesis is exploring if the therapeutic index is improved by eliminating the third dose. Early data suggest that Schedule B is better tolerated by patients, while maintaining anti-leukemic activity. New data on the 21 patients on Schedule B reported on at ASH indicate 6 have achieved a CR or CRp, while 2 are awaiting hematologic count recovery. In addition to improved tolerability, the 30-day all-cause mortality rate has been reduced to 5 percent (1 of 21).

Additionally, the company is rapidly accruing relapsed or refractory AML patients in a Phase 1b/2 clinical trial testing voreloxin in combination with cytarabine given by continuous infusion (Schedule A) or by 2 hr IV infusion (Schedule B). At ASH, Sunesis reported that a maximum tolerated dose (MTD) of 80 mg/m2 was established for Schedule A, with 9 CRs or CRps reported in the Phase 1b dose escalation. The Phase 2 portion of this study has now enrolled eight patients with AML in first relapse at the Schedule A MTD and complete remissions have been observed. In addition, Schedule B has completed safety assessment for the first cohort without dose limiting toxicities, and the second cohort is now enrolling at 80 mg/m2 of voreloxin.

"We are extremely pleased by these interim results for both of our AML studies. In the REVEAL-1 study, overall tolerability has improved with the amended dose regimen, while maintaining activity," said Steve Ketchum, Senior Vice President,
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  UBM Medica US ... a leading online community to help oncologists and ... newest information available regarding the use of targeted ... cancer. March is National Kidney ... few effective adjuvant treatment options for renal cell ...
(Date:3/5/2015)... e2b teknologies , a premier Sage ERP ... today announced a leading independent multi-specialty physician group practice ... the latest version of Sage 100 ERP . ... kind in the region, the organization has an extensive ... and data accessibility are paramount to their ongoing success. ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... , 3.75% Convertible Senior Notes due May 1, ... per $1,000 principal amount or approximately $5.72 per share, effective ... note is adjusted in connection with the regular quarterly dividend ... stockholders who own shares of PDL on March 5, 2015, the ...
(Date:3/4/2015)... 2015  Brooklyn residents now have a new place ... and injuries. Nunzio Saulle , M.D., a board-certified ... his NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 5, 2015. Health Plus Management, LLC is managing the ... 1178 Flatbush Avenue. This new PM&R practice will treat ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... Experience To Antimicrobial Leader.SHREVEPORT, La., March 23 ... in the poultry industry, has joined SteriFx Inc. ... to SteriFx, a leader in developing non-toxic antimicrobial ... defense and other industries. "We,re honored and thrilled ...
... DIEGO, March 23 Nereus Pharmaceuticals, Inc., a ... today announced that it is conducting a randomized ... agent (VDA) NPI-2358 in combination with standard chemotherapy ... (NSCLC). This study follows on positive outcomes ...
... Based on its recent analysis of ... Sullivan presents Nanopoint, Inc. with the 2009 ... Product Innovation of the Year. The company,s ... sophisticated, on-microscope incubator and integrated fluidics system ...
Cached Biology Technology:Dan Blackshear Joins SteriFx Inc. 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 2Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 4Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 5
(Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... "engineered" a mouse that can run on a treadmill ... its supply of acetylcholine, the neurotransmitter essential for muscle ... Neuroscience, could lead to new treatments for neuromuscular disorders ... signals fail to reach the muscles, said Randy Blakely, ...
... objects create blurry images in photography, and the same ... constantly in motion, such as the breathing lung. ... a method to stabilize living lung tissue for imaging ... method allowed the team to observe, for the first ...
... Maritime transport causes about 4% of global man-made ... as high as Germany,s. There is no regulation ... is currently under discussion in the International Maritime ... Convention on Climate Change (UNFCCC). In respect of ...
Cached Biology News:Boosting supply of key brain chemical reduces fatigue in mice 2New imaging advance illuminates immune response in breathing lung 2New imaging advance illuminates immune response in breathing lung 3Reducing emissions from shipping: Commission's Joint Research Centre sets out some options 2Reducing emissions from shipping: Commission's Joint Research Centre sets out some options 3
... ErbB 2 - BSA and Azide ... tested applications). Antigen: ... KLH, corresponding to C terminal amino ... Entrez GeneID: 2064 ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: